Interleukin-2 receptor-directed therapies for cutaneous lymphomas

Hematol Oncol Clin North Am. 2003 Dec;17(6):1449-58. doi: 10.1016/s0889-8588(03)00110-2.

Abstract

Our emerging understanding of the IL-2/IL-2R system opens the possibility for more specific immunotherapy of CTCL. This understanding, taken in conjunction with the ability to produce humanized antibodies to the IL-2R subunit by genetic engineering; to arm these antibodies, as well as IL-2 itself with toxins or with alpha- and beta-emitting radionuclides; and to modulate IL-2R subunits to optimize targeting of these agents provides a rational therapeutic strategy for the treatment of IL-2R-expressing CTCL. Although most of these studies were conducted in HTLV-1-associated T-cell lymphomas or CTCL, it is likely that these agents may be applicable to other T-cell lymphomas, including the anaplastic large cell lymphomas, peripheral T-cell lymphomas, and the natural killer lymphomas, because these cells express the IL-2 receptor.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Clinical Trials as Topic
  • Diphtheria Toxin / therapeutic use
  • Drug Delivery Systems
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Immunoconjugates / therapeutic use
  • Immunotherapy
  • Immunotoxins / therapeutic use
  • Interleukin-2 / physiology
  • Interleukin-2 / therapeutic use
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / metabolism
  • Lymphoma, T-Cell, Cutaneous / radiotherapy
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / immunology
  • Neoplasm Proteins / physiology
  • Protein Isoforms / antagonists & inhibitors
  • Protein Isoforms / genetics
  • Protein Subunits
  • Receptors, Interleukin-2 / antagonists & inhibitors*
  • Receptors, Interleukin-2 / genetics
  • Receptors, Interleukin-2 / immunology
  • Receptors, Interleukin-2 / physiology
  • Recombinant Fusion Proteins / therapeutic use
  • Retinoids / pharmacology
  • Retinoids / therapeutic use
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / radiotherapy

Substances

  • Antibodies, Monoclonal
  • Diphtheria Toxin
  • Immunoconjugates
  • Immunotoxins
  • Interleukin-2
  • Neoplasm Proteins
  • Protein Isoforms
  • Protein Subunits
  • Receptors, Interleukin-2
  • Recombinant Fusion Proteins
  • Retinoids
  • interleukin 2-diphtheria toxin